THE WIRE · № 64052
CSL and Alentis announce global partnership to develop and commercialise lixudebart for rare kidney and liver diseases
01 THE MACHINE READ
WHY IT MATTERS.
A large upfront and milestone deal signals continued pharma licensing appetite for rare-disease assets, but neither company is in the allowed ticker list.
Rare-disease licensing stays active despite biotech funding caution
Trial progress or regulatory filings for lixudebart
Milestones may never be reached if trials fail
FULL DISPATCH
Alentis to receive US$355 million initial payment and up to US$1.2 billion in commercial milestones, with global profits shared MELBOURNE, Australia and BASEL, Switzerland, Oct. 4, 2026 /PRNewswire/ -- CSL and Alentis Therapeutics today announced they have entered into an exclusive global...
02 THE STORY SO FAR
THE RECORD, IN ORDER.
STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.
03 WHO'S INVOLVED
ENTITIES ON FILE.
04 RECEIPTS
THE SOURCE RECORD.
1 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
Trump finally taps fund, along with favored nations deals, to significantly cut costs for seniors2026-10-03 02:59 UTC
Aetna 2027 Medicare plans offer reliable, affordable access to care & member support2026-10-03 11:00 UTC
Ractigen Therapeutics Presents Positive First-in-Human Data for RAG-18 at WMS 2026, Establishing Clinical Proof-of-Mechanism for RNA Activation in Duchenne Muscular Dystrophy2026-10-03 11:30 UTC
SIBIONICS and PharmaSens Explore New Horizons for Automated Insulin Delivery at EASD 20262026-10-04 03:09 UTC
Sandoz Agrees to $400 Million Deal to Resolve States’ Generic-Drug Antitrust Case2026-10-04 15:40 UTC
Late-Breaking Clinical Trial Results Announced at The VEINS 20262026-10-04 21:16 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.